Iceland Screens, Treats or Prevents Multiple Myeloma (iStopMM)
Monoclonal Gammopathy of Undetermined Significance
About this trial
This is an interventional screening trial for Monoclonal Gammopathy of Undetermined Significance focused on measuring MGUS, Screening, Population-based
Eligibility Criteria
Inclusion Criteria:
- Born 1975 or earlier
- With registered address in Iceland on November 1st 2016
Exclusion Criteria:
- Prior multiple myeloma
- Lymphoproliferative disease
- Amyloidosis
- M-protein >30 g/L or involved:uninvolved serum FLC ratio >100
Individuals with prior history of MGUS will be offered to be randomized into either moderate or intensive clinical follow-up (arms 2 or 3).
Sites / Locations
- University of Iceland
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Arm 6
Active Comparator
Experimental
Experimental
Experimental
Active Comparator
Active Comparator
Abnormal Non-MGUS
MGUS group arm 1
MGUS group arm 2
MGUS group arm 3
Normal group
Controls
Participants previously diagnosed with MGUS, multiple myeloma or other lymphoproliferative disease.
Participants diagnosed with MGUS, randomized to group 1.
Participants diagnosed with MGUS, randomized to group 2.
Participants diagnosed with MGUS, randomized to group 3.
Participants without MGUS.
Participants without MGUS, matched to MGUS participants by age and gender.